A recent survey conducted by market research firm Spherix Global Insights revealed that fewer than half of neurologists are recommending the drug Leqembi to their patients with Alzheimer’s disease. The satisfaction rate for the drug is significantly lower than the typical rating for a new entrant in the neurology market, with many patients facing challenges in obtaining coverage for the treatment from Medicare or private insurers.
In a press release, Spherix Global Insights highlighted the frustrations faced by patients due to high co-pays and difficulties in accessing the required infusions. Despite Biogen’s announcement of 3,800 patients on Leqembi, neurologists continue to struggle with the testing and logistical requirements for prescribing the drug effectively.
Furthermore, opinions among neurologists are divided on the effectiveness of lowering beta-amyloid as a treatment for early-onset Alzheimer’s disease. The survey indicates a need for greater accessibility and affordability for patients seeking treatment with Leqembi.
